Comparison of Development of Thyroid Disorders in patients of Chronic Hepatitis C Being Treated with Interferon Alpha Versus Pegylated Interferon
نویسندگان
چکیده
Aim: To compare the frequency of thyroid disorders in patients of chronic hepatitis C being treated with interferon alpha versus pegylated interferon. Methods:: This randomized Controlled Trial was conducted at Department of Medicine, Bahawal Victoria Hospital, Bahawalpur from October 2014 to April 2015.A total of 340 diagnosed case of chronic hepatitis C by PSR HCV RNA of both genders, having age range between 25 years to 60 years, were included in the study. Results: The average age of cases in group A& B was as35.73 ± 7.31years and 35.91 ± 8.24years respectively. Out of these 340 patients, 201 (59.12%) were male and 139 (40.88%) were females with ratio of 2.09:1. Mean thyroid stimulating hormone level was 2.31 ± 1.12 in group A and 2.46 ± 0.98 in group B. Thyroid disorder was seen in 15 (8.82%) patients in conventional interferon therapy group and 31 (18.24%) patients in pegylated interferon therapy group with p-value of 0.011. Conclusion: This study concluded that the frequency of thyroid disorders is lower in patients of chronic hepatitis C being treated with interferon alpha compared to pegylated interferon with higher frequency among females in both groups.
منابع مشابه
Impact of “Sambhav” Program (Financial Assistance and Counselor Services) on Hepatitis C Pegylated Interferon Alpha Treatment Initiation in India
Background Financial constraints, social taboos and beliefs in alternative medicine are common reasons for delaying or not considering treatment for hepatitis C in India. The present study was planned to analyze the impact of non-banking interest free loan facility in patients affected with hepatitis C virus (HCV) in North India. Methods This one year observational, re...
متن کاملAmantadine Plus Interferon-α Versus Interferon-α Monotherapy for the Treatment of Chronic Hepatitis-C Infection in β-Thalassemia Major Patients: A Randomized Double Blinded Pilot Study in Shiraz, Iran
Background: Hepatitis-C infection is a major problem in chronically transfused patients. We compared Interferon-α (INF-α) monotherapy with combination of INF-α and amantadine in the treatment of β-thalassemia major patients who were chronically infected with HCV.Materials and Methods: Forty six thalassemia major patients who were chronically infected with HCV were randomly divided into two grou...
متن کاملVitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)
α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...
متن کاملبررسی اثر آلفا انترفرون در 16 بیمار مبتلا به هپاتیت مزمن ویروسی
Alpha-interferon therapy has been approved for treatment of chronic hepatitis C and B. Candidates for treatment are patients with well-compensated liver disease and histologic evidences of chronic hepatitis who have demonstrated abnormal aminotransferase levels for more than 6 months. From 30 patients with chronic hepatitis with diseases prolonged more than 6 months, we selected only 16 patient...
متن کاملSevere muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication
Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFN^5. Case Presentation: In this report, we describe a case with se...
متن کامل